Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

Gastroenterology - United Kingdom
doi 10.1053/j.gastro.2019.05.067
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease

Gastroenterology
HepatologyGastroenterology
2018English

Psy114 - Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy in Patients With Crohn’s Disease in the United Kingdom (Uk)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Effects of Vedolizumab in Japanese Patients With Crohn’s Disease: A Prospective, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial With Exploratory Analyses

Journal of Gastroenterology
Gastroenterology
2019English

Adalimumab for Endoscopic and Histopathological Mucosal Healing in Paediatric Patients With Moderate to Severe Crohn’s Disease

Przeglad Gastroenterologiczny
Gastroenterology
2017English

Crohn’s Disease Remission With a Plant-Based Diet: A Case Report

Nutrients
NutritionFood ScienceDietetics
2019English

Update of Endoscopic Management of Crohn’s Disease Strictures

Intestinal Research
Gastroenterology
2020English

A Clinical Decision Support Tool May Help to Optimise Vedolizumab Therapy in Crohn’s Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Activity-Based Costing and Budget Analysis of Vedolizumab Versus Conventional Treatments in Ulcerative Colitis and Crohn’s Disease

Global and Regional Health Technology Assessment
Health Policy
2017English

Dental Caries, Prevalence and Risk Factors in Patients With Crohn’s Disease

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy